Table 3.
Ongoing clinical trials for older/unfit patients with AML.
| Clinical Trial | Phase | Status | Study Drugs | Setting |
|---|---|---|---|---|
| NCT03416179 | PhaseIII | Recruiting | Glasdegib + Azacitidine vs. Glasdegib + placebo | Previously untreated unfit patients with ND AML |
| NCT02577406 | PhaseIII | Recruiting | Enasidenib vs. Azacitidine or Intermediate-dose Cytarabine | Patients 60 years or older with R/R AML after second- or third-line therapy with a susceptible IDH2 mutation. |
| NCT03173248 | PhaseIII | Recruiting | Ivosidenibb vs. Azacitidine or Intermediate-dose Cytarabine | Previously untreated unfit patients with ND AML and a susceptible IDH1 mutation. |
| NCT02993523 | PhaseIII | Active/not recruiting | Venetoclax + Azacitidine vs. Venetoclax + Placebo | Previously untreated unfit patients with ND AML |
| NCT03069352 | PhaseIII | Active/not recruiting | Venetoclax + low dose Cytarabine vs. low dose Cytarabine | Previously untreated unfit patients with ND AML |
| NCT01093573 | PhaseI/II | Active/not recruiting | Azacitidine + Midostaurin | Previously untreated unfit patients with ND AML |
| NCT02172872 | PhaseIII | Active/not recruiting | 10-day Decitabine vs. + Standard chemotherapy followed by Allografting | Fit patients 60 years or older with previously untreated ND AML |